Sanofi Says It Won EU Patent Ruling Against Amgen Over Cholesterol Drug -- Update
October 29 2020 - 12:12PM
Dow Jones News
(Adds comments from Amgen)
By Kim Richters
Sanofi SA said Thursday that the European Patent Office has
ruled in favor of Sanofi and Regeneron Pharmaceuticals Inc. in a
patent case related to their cholesterol drug Praluent.
The French pharmaceutical company said the European authority's
ruling invalidated certain European patent claims made by Amgen
Inc. concerning PCSK9 antibodies relevant to the drug.
"Amgen is disappointed in the decision by the EPO's technical
board of appeal denying patent protection" to some of Amgen's
patent claims a spokeswoman for the U.S. pharmaceutical company
told The Wall Street Journal.
"Amgen led the way in deciphering the role of PCSK9 and was the
first company in the world to invent a class of monoclonal
antibodies that have proven to provide therapeutic benefit by
inhibiting the protein PCSK9. We firmly believe that the original
scope of patent protection granted for this significant
contribution was appropriate and valid," the spokeswoman added.
Sanofi said it owns the rights for the drug outside of the U.S.,
while Regeneron holds them inside the country.
Praluent continues to be on the market in the European countries
where it is approved, with the exception of Germany after an
injunction in July last year, which Sanofi said it has
appealed.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
October 29, 2020 11:57 ET (15:57 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Sep 2023 to Sep 2024